Introduction: PCOS Meets GLP-1
Polycystic ovary syndrome (PCOS) affects an estimated 8–13% of reproductive-age women worldwide, making it the most common endocrine disorder in this population. At its core, PCOS is not just a reproductive condition — it is fundamentally a metabolic disorder. Insulin resistance sits at the center of the pathophysiology for the majority of women with PCOS, driving both the metabolic complications (weight gain, dyslipidemia, progression to type 2 diabetes) and the reproductive manifestations (hyperandrogenism, anovulation, infertility).
For decades, metformin has been the go-to pharmacological intervention for the metabolic component of PCOS. It improves insulin sensitivity, modestly aids weight management, and can help restore ovulatory function. But metformin is not a weight-loss drug — its effects on body weight are typically modest at best, and many women with PCOS struggle with significant obesity that metformin alone cannot address.
Enter the GLP-1 receptor agonists. Medications like Ozempic (semaglutide), Wegovy, Mounjaro (tirzepatide), and Saxenda (liraglutide) have transformed the landscape of obesity medicine. Their potent effects on appetite regulation, gastric emptying, and insulin secretion have raised an important question: could these medications offer something unique for women with PCOS? The emerging evidence suggests the answer is yes — and the research is expanding rapidly.
The Insulin–PCOS Connection: Why GLP-1s Make Theoretical Sense
To understand why GLP-1 receptor agonists might be particularly effective in PCOS, you need to understand the insulin–androgen axis.
In PCOS, insulin resistance leads to compensatory hyperinsulinemia — the pancreas pumps out more insulin to maintain normal blood glucose levels. Elevated circulating insulin has two critical effects on the ovaries:
- Direct stimulation of theca cells: Insulin acts on ovarian theca cells to increase androgen (testosterone and androstenedione) production.
- Reduced SHBG production: High insulin levels suppress hepatic synthesis of sex hormone-binding globulin (SHBG), the protein that binds testosterone in circulation. Less SHBG means more free, biologically active testosterone.
The result is a vicious cycle: insulin resistance → hyperinsulinemia → increased ovarian androgen production + decreased SHBG → hyperandrogenism (acne, hirsutism, scalp hair loss) → worsening insulin resistance through androgen-mediated visceral adiposity.
GLP-1 receptor agonists interrupt this cycle at multiple points. By enhancing glucose-dependent insulin secretion, they reduce the need for compensatory hyperinsulinemia. By delaying gastric emptying and promoting satiety, they drive meaningful weight loss — and adipose tissue loss directly improves insulin sensitivity. The theoretical rationale is strong, and clinical data is now catching up.
Clinical Evidence: What the Research Actually Shows
The body of evidence for GLP-1 receptor agonists in PCOS has grown substantially in recent years, though it remains smaller than the evidence base for type 2 diabetes and general obesity.
Systematic Reviews and Meta-Analyses
A 2026 systematic review and meta-analysis published in the European Journal of Endocrinology assessed the effect of GLP-1 receptor agonist treatment in women with PCOS across 11 randomized controlled trials. The findings confirmed that GLP-1 RAs as an add-on therapy significantly reduced BMI compared to control groups, with a mean difference of −1.38 kg/m². The review concluded that these agents improve weight-related and metabolic outcomes in PCOS, though the authors noted that the certainty of evidence ranged from low to moderate and called for larger, longer-duration trials PMID: 41701618.
A separate 2025 meta-analysis published in Scientific Reports, encompassing multiple RCTs, found that GLP-1 receptor agonists were superior to both metformin and placebo for weight management in women with PCOS. Beyond weight, the analysis demonstrated significant improvements in waist circumference, fasting insulin, and HOMA-IR (a measure of insulin resistance), along with reductions in total testosterone levels PMID: 40360648.
A 2026 network meta-analysis in the Journal of Ovarian Research compared the efficacy of novel antidiabetic agents — including SGLT2 inhibitors, GLP-1 receptor agonists, and tirzepatide — in PCOS. The analysis confirmed that GLP-1 RAs ranked among the most effective interventions for weight loss and metabolic improvement in this population PMID: 41862977.
Liraglutide: The Most-Studied GLP-1 in PCOS
Liraglutide (Saxenda, Victoza) has the most robust clinical trial data in PCOS to date. A pivotal 2022 randomized, double-blind, placebo-controlled phase 3 trial published in Fertility and Sterility evaluated liraglutide 3.0 mg versus placebo over 32 weeks in women with obesity and PCOS. The study demonstrated significant reductions in body weight and free androgen index (FAI), confirming that liraglutide addresses both the weight and the hyperandrogenic components of PCOS simultaneously PMID: 35710599.
A comprehensive 2026 systematic review and meta-analysis focused specifically on liraglutide in overweight and obese women with PCOS, published in Diabetes, Obesity and Metabolism, confirmed improvements across both metabolic and reproductive outcomes. The analysis pooled data from multiple RCTs and found that liraglutide — particularly when combined with metformin — outperformed metformin alone on weight, insulin resistance, and menstrual regularity endpoints PMID: 41508932.
Semaglutide (Ozempic/Wegovy): Emerging Data
Direct clinical trial data for semaglutide in PCOS is more limited than for liraglutide, but the studies that do exist are promising. A 2025 prospective, randomized, controlled, open-label trial published in Reproductive Biology and Endocrinology compared metformin monotherapy (1000 mg twice daily) to combination therapy (metformin plus semaglutide 1.0 mg once weekly) over 16 weeks in 100 overweight or obese women with PCOS. The combination group showed superior improvements in body weight, metabolic parameters, reproductive hormone levels, and inflammatory markers including C-reactive protein PMID: 40713699.
An earlier study from 2023, published in Diabetes, Obesity and Metabolism, specifically examined semaglutide’s effect on gastric emptying in women with PCOS and obesity. Using technetium scintigraphy — the gold standard for gastric emptying measurement — researchers found that semaglutide 1.0 mg significantly delayed gastric emptying. At 4 hours post-meal, the semaglutide group retained 37% of the solid meal in the stomach compared to no gastric retention in the placebo group. This pronounced delay in gastric emptying likely contributes to the enhanced satiety and reduced caloric intake that drives semaglutide’s weight loss effects PMID: 36511825.
Weight Loss Outcomes in PCOS Patients on GLP-1s
Weight loss is arguably the most consistent and clinically meaningful outcome demonstrated by GLP-1 receptor agonists in PCOS. Across the meta-analyses, GLP-1 RAs consistently produce greater weight loss than metformin, placebo, or lifestyle intervention alone.
The liraglutide phase 3 trial demonstrated significant reductions in body weight and body composition by DEXA scan over 32 weeks. The combination trials pairing GLP-1 RAs with metformin consistently show additive benefits — the two medications work through complementary mechanisms. Metformin primarily reduces hepatic glucose output and modestly improves peripheral insulin sensitivity, while GLP-1 RAs target appetite, gastric emptying, and glucose-dependent insulin secretion.
For women with PCOS who carry significant excess weight — and an estimated 40–80% of women with PCOS are overweight or obese — this weight loss can be transformative. Even modest weight loss of 5–10% of body weight has been shown to restore ovulatory function and improve pregnancy rates in PCOS, independent of any direct pharmacological effect on the ovary.
Hormonal Improvements: Testosterone, SHBG, and Menstrual Regularity
The hormonal effects of GLP-1 receptor agonists in PCOS are particularly important because they speak directly to the symptoms that distress many patients — hirsutism, acne, irregular periods, and infertility.
The 2025 Scientific Reports meta-analysis specifically examined hormonal outcomes and found that GLP-1 RAs significantly reduced total testosterone levels compared to both placebo and metformin. The mechanism is likely twofold: weight loss reduces adipose-derived androgen production, and improved insulin sensitivity reduces hyperinsulinemia-driven ovarian androgen synthesis. As insulin levels fall, hepatic SHBG production increases, which further reduces free testosterone levels by binding more of the circulating androgen PMID: 40360648.
Menstrual regularity — a proxy for ovulatory function — has been assessed in several trials. The combination therapy approach (GLP-1 RA plus metformin) has shown particular promise for restoring regular menstrual cycles. The 2025 semaglutide combination trial explicitly examined reproductive outcomes, finding that the addition of semaglutide to metformin improved reproductive hormone profiles compared to metformin alone PMID: 40713699.
Fertility Implications and the Critical Pregnancy Precaution
This brings us to what is arguably the most important clinical consideration for women with PCOS considering GLP-1 medications: the intersection with fertility.
PCOS is the leading cause of anovulatory infertility. By improving insulin sensitivity, reducing weight, and lowering androgen levels, GLP-1 receptor agonists can restore ovulatory function — which means they can also restore fertility. This is a desired outcome for women trying to conceive, but it comes with a critical warning.
GLP-1 receptor agonists must be discontinued at least two months before a planned pregnancy. These medications are classified as pregnancy category contraindicated based on animal studies showing potential fetal harm. Women who may become pregnant while taking Ozempic, Wegovy, Mounjaro, or similar medications need effective contraception and careful planning.
A 2022 long-term follow-up study of an RCT, published in the Archives of Gynecology and Obstetrics, compared exenatide (a first-generation GLP-1 RA) to metformin in 160 overweight or obese infertile women with PCOS. The study tracked spontaneous pregnancy rates, ART-assisted pregnancy rates, and pregnancy outcomes through delivery. While the GLP-1 RA was used only during the initial 12-week intervention period (after which all patients continued on metformin alone), the results provided important proof-of-concept that GLP-1 RA treatment in the preconception window can be compatible with subsequent healthy pregnancies when the medication is discontinued before conception PMID: 35829765.
The clinical takeaway is nuanced: GLP-1 RAs can be a powerful tool for improving fertility potential in PCOS by addressing the underlying metabolic dysfunction, but they are not fertility drugs per se and must be stopped before pregnancy. Many reproductive endocrinologists now view a course of GLP-1 RA therapy as a “metabolic optimization” step prior to ovulation induction or ART.
GLP-1s vs. Metformin: The Emerging First-Line Debate
Metformin has been the default metabolic intervention for PCOS for over two decades. It is inexpensive, generally well-tolerated, and has an excellent safety track record — including during pregnancy (it is commonly continued through the first trimester in PCOS patients undergoing fertility treatment).
However, the weight of evidence increasingly favors GLP-1 receptor agonists when weight loss is a primary goal. The meta-analyses consistently show that GLP-1 RAs produce significantly greater reductions in body weight, BMI, and waist circumference than metformin. A 2025 systematic review in Diabetes, Obesity and Metabolism examining combined liraglutide and metformin therapy confirmed that the combination outperforms metformin alone across metabolic, hormonal, and reproductive endpoints PMID: 40855964.
The comparison is not necessarily “either-or.” Many clinicians are adopting a combination approach: metformin as the foundational insulin sensitizer, with a GLP-1 RA added for patients who need more substantial weight loss or who have not achieved metabolic targets on metformin alone. The preclinical data even suggests potential synergistic gut microbiome effects from the combination PMID: 41384017.
Practical Considerations for Women with PCOS
Off-Label Status
It is important to note that Ozempic (semaglutide) is FDA-approved for type 2 diabetes, and Wegovy (the same drug at a higher dose) is approved for obesity. Neither is specifically approved for PCOS. Prescribing GLP-1 RAs for PCOS is an off-label use — one that is increasingly common and evidence-supported, but off-label nonetheless. This has implications for insurance coverage.
Insurance and Cost
In the United States, insurance coverage for GLP-1 medications in PCOS without a comorbid diagnosis of type 2 diabetes or a BMI ≥30 (or ≥27 with a weight-related comorbidity) can be challenging. Many insurers require step therapy (trying metformin first), prior authorization, and documentation of PCOS diagnosis with metabolic complications. Patients should work with their prescribing physician to document the medical necessity thoroughly.
Side Effect Profile in PCOS
The gastrointestinal side effects of GLP-1 RAs — nausea, vomiting, diarrhea, constipation — appear similar in PCOS patients compared to the general population. However, the delayed gastric emptying that is part of the therapeutic mechanism can be pronounced. The 2023 gastric emptying study found that semaglutide retained 37% of a solid meal in the stomach at 4 hours, which explains why early satiety and nausea are common, particularly during dose titration PMID: 36511825.
Starting at a low dose and titrating slowly — following the standard schedules used for diabetes and obesity — appears equally important in PCOS patients.
The Mounjaro (Tirzepatide) Question
Tirzepatide (Mounjaro, Zepbound), the dual GIP/GLP-1 receptor agonist that has shown even greater weight loss than semaglutide in obesity trials, has very limited published data specifically in PCOS. However, the network meta-analysis published in 2026 included tirzepatide among the novel antidiabetic agents evaluated for PCOS, suggesting that dedicated PCOS trials are either underway or being planned PMID: 41862977. Given tirzepatide’s superior weight loss profile in the general population, there is considerable interest in its potential for the PCOS population.
Conclusion: A Promising but Evolving Picture
The evidence supporting GLP-1 receptor agonists in PCOS is growing rapidly and points in a consistent direction: these medications offer significant benefits for weight loss, insulin resistance, and hyperandrogenism in women with PCOS. The combination of GLP-1 RA with metformin appears particularly effective, leveraging complementary mechanisms to address both the metabolic and reproductive dimensions of the syndrome.
Key takeaways from the current evidence:
- Weight loss: GLP-1 RAs consistently outperform metformin and placebo for weight reduction in PCOS, with BMI reductions of approximately 1.4 kg/m² in meta-analyses.
- Hormonal improvements: Reductions in total testosterone and free androgen index are consistently reported across trials.
- Menstrual regularity: Restored ovulatory function and improved menstrual cyclicity have been documented, particularly with combination therapy.
- Fertility: Improved fertility potential is a double-edged sword — it is a desired outcome but requires careful contraceptive planning, as GLP-1 RAs must be stopped before pregnancy.
- Evidence gaps: Larger, longer-duration trials are still needed, and data on semaglutide and tirzepatide specifically in PCOS remains limited compared to liraglutide.
For women with PCOS who struggle with weight despite lifestyle modification and metformin, GLP-1 receptor agonists represent an evidence-based, increasingly utilized treatment option. As always, treatment decisions should be made in partnership with a healthcare provider who understands both the metabolic and reproductive dimensions of PCOS.
References
Forslund M, Wändell P, Forsberg L, et al. GLP-1 receptor agonist treatment in women with polycystic ovary syndrome — a systematic review and meta-analysis. Eur J Endocrinol. 2026. PMID: 41701618
Lin S, Deng Y, Huang J, et al. Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials. Sci Rep. 2025. PMID: 40360648
Chen H, Lei X, Yang Z, et al. Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial. Reprod Biol Endocrinol. 2025. PMID: 40713699
Elkind-Hirsch KE, Chappell N, Shaler D, et al. Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study. Fertil Steril. 2022. PMID: 35710599
Lu YT, Chang PH, Chen HJ, et al. Efficacy of liraglutide on metabolic and reproductive outcomes in women with polycystic ovary syndrome: A systematic review and meta-analysis. Diabetes Obes Metab. 2026. PMID: 41508932
Jensterle M, Ferjan S, Ležaič L, et al. Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity. Diabetes Obes Metab. 2023. PMID: 36511825
Li R, Mai T, Zheng S, et al. Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT. Arch Gynecol Obstet. 2022. PMID: 35829765
Lin J, Yang R, Zhuang J, et al. The efficacy and safety of novel antidiabetic agents in polycystic ovary syndrome: a network meta-analysis. J Ovarian Res. 2026. PMID: 41862977
Disclaimer: This article is for informational purposes only and does not constitute medical advice. GLP-1 receptor agonists are prescription medications that should only be used under the supervision of a qualified healthcare provider. Always consult your physician before starting, stopping, or changing any medication.
